RxDoctor Payments Data

Shahla Amrooei

Family · Tampa, FLNPI 1922089838

Payments from drug & device makers

$1,030in general payments, 2019–2025

Across 51 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$183
  • AstraZeneca$173
  • Lilly USA, LLC$142
  • Pfizer$109
  • AbbVie$73
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$43
  • plus $307 from 12 others

What the payments were for

  • Food & beverage$1,030100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,030 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$10,106
Medicare patients
56
Services billed
115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$18,497
OzempicSemaglutide18$17,831
VascepaIcosapent Ethyl16$10,853
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,611
Gabapentin38$1,031
Rosuvastatin Calcium47$771
Albuterol Sulfate HfaAlbuterol Sulfate39$688
Diclofenac Sodium22$603
Duloxetine Hcl12$414
Fluticasone Propionate29$407
Metoprolol Succinate21$347
Famotidine16$346
Omeprazole14$309
Metformin Hcl47$285
Ibuprofen18$280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$109$18,49715 claims
Novo NordiskOzempic$183$17,83118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 14,618 family providers in Florida.

Other family in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →